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Rationale: We still do not know why some subjects with airway hyperresponsiveness
(AHR) experience no respiratory symptoms.
Objectives: Our aim was to compare pulmonary function, perception of broncho-
constriction, and airway inflammation in atopic subjects with mild recently
diagnosed (o5 years, n ¼ 30) or longer-standing (5 years or more, n ¼ 30)
symptomatic asthma in comparison with atopic subjects with asymptomatic AHR
(n ¼ 27).
Methods: All subjects had measurements of expiratory flows, PC20 methacholine,
perception of breathlessness and induced sputum cell differential, eosinophil
cationic protein and a2-macroglobulin levels.
Results: Compared with the other groups, PC20 was significantly lower in longer-
standing asthma and perception score for breathlessness at 20% fall in FEV1 was
lower in asymptomatic subjects. Markers of airway inflammation were similar in all
groups. There were no significant correlations between sputum eosinophils,Elsevier Ltd. All rights reserved.
ough a Canadian Institute of Health Research (CIHR)/Industry program.
56 4747; fax: +1 418 656 4762.
al.ca (L.-P. Boulet).
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Mild asthma vs. asymptomatic AHR 293a2-macroglobulin and/or eosinophil cationic protein levels and FEV1, FVC or PC20 in
either group.
Conclusion: Subjects with mild asthma or asymptomatic AHR are similar in regard to
induced sputum markers of airway inflammation. Although perception of broncho-
constriction was slightly lower in asymptomatic subjects, additional factors are
probably involved to explain why they report no respiratory symptoms. Further
studies are needed to determine why these last are asymptomatic.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Airway hyperresponsiveness (AHR) is observed in
almost all subjects with symptomatic asthma and is
described as a property of the airways to respond
both too much and too easily to various stimuli.1 In
the general population, airway responsiveness
follows a continuous unimodal log-normal distribu-
tion, with asthmatic subjects representing the
‘‘hyperresponsive’’ end of the distribution curve.2
A variable proportion of asymptomatic subjects, up
to 50% in some studies, with no past or present
history of asthma, show an increased airway
response to agents such as histamine or methacho-
line or to stimuli such as exercise.3,4 Although the
significance of such AHR in the absence of
symptoms is still uncertain, it has been considered
a risk factor for asthma, particularly in atopic
subjects; these subjects are possibly at an early
stage of a process that may lead to the classical
features of symptomatic asthma.5–7 In this regard,
asymptomatic AHR has been associated with airway
wall inflammation and remodeling, although these
features were less marked than in asthmatic
subjects.6
There are a number of possible explanations for
the absence of symptoms in subjects with increased
airway responsiveness. These include a too-high
cut-off of PC20, the provocative concentration of
methacholine giving a 20% fall in forced expiratory
volume in 1 s (FEV1), that does not reflect an
abnormal airway behavior; intermittent AHR; mini-
mal variability of airway obstruction; insufficient
airway inflammation/remodeling; or a defective
perception of airway obstruction.5
More studies are needed to look at clinical and
physiological features of asymptomatic AHR, in
order to better understand why some subjects with
AHR have no symptoms. In the present study, our
hypotheses were that subjects with asymptomatic
AHR had less evidences of airway inflammation than
in asthma, those with recently diagnosed asthma
being intermediary between longer-standing asth-
ma and asymptomatic AHR. We therefore assessed
inflammatory cell levels, as well as markers of
inflammation such as eosinophil cationic protein(ECP) and a2-macroglobulin. ECP is a cytotoxic
protein released from activated eosinophil during
the inflammatory process,8,9 while a2-macroglobu-
lin has been previously validated as a marker of
plasma exudation, a process that could contribute
to airway obstruction and hyperresponsive-
ness.10–12 ECP and a2-macroglobulin have previously
been successfully measured in induced sputum.13–16
Furthermore, we wanted to gather more data on
perception of induced bronchoconstriction in these
groups.Methods
Subjects
We enrolled non-smoking atopic subjects currently
exposed to relevant allergens with either mild
asthma ðn ¼ 60Þ or asymptomatic AHR ðn ¼ 27Þ with
a PC20 between 1 and 16mg/ml. The asthma group
included subjects with recently diagnosed (o5
years, n ¼ 30) or longer-standing (X5 years,
n ¼ 30) asthma. These subjects were recruited
from our Asthma and Respiratory Allergy clinics or
from advertisements in local media. This analysis
was done on all subjects initially studied, some
being thereafter included in another long-term
study looking at the influence of anti-inflammatory
treatment on airway inflammation in those groups.
Additional inclusion criteria were, for all subjects
(1) Men or women 18–45 years old; (2) at least one
positive (X3mm wheal at 15min) response to
indoor allergens (cat, dog, house-dust mite or
cockroach). Additional exclusion criteria were (1)
respiratory infection within 6 weeks of the first visit
of the study, (2) smoking410 packs-years, or in the
last twelve months and (3) pregnancy, breastfeed-
ing or inadequate contraception.
Mild asthma was defined as: mild intermittent
asthma symptoms, less than twice a week over the
last 3 months; demonstration of variable airflow
obstruction according to the 1999 Canadian asthma
consensus criteria;17 inhaled short-acting b2 agonist
on demand as the only medication required for
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asthma group into those with a diagnosis of 5 years
or less versus more than 5 years to determine
if subjects with more recently diagnosed asthma
had features closer to those with asymptomatic
AHR.
Subjects were considered to have asymptomatic
AHR if they had shown no past or present symptoms
of intermittent dyspnea or wheezing, chronic cough
or phlegm production as defined by negative
responses to the European community respiratory
health survey (ECRHS) questionnaire18 and no
symptoms similar to those induced by the metha-
choline challenge. Each subject signed an informed
consent form, approved by the Ethics Committee of
the hospital.Study design
Subjects had a detailed respiratory questionnaire,
skin-prick tests, methacholine bronchoprovocation
with measurement of perception of bronchocon-
striction and an induced sputum sampling.
The ECRHS questionnaire was used for screening
and for evaluating associated conditions.18 Addi-
tional questions were asked about subjects’ char-
acteristics, perceived symptoms, smoking, duration
and control of asthma and its treatment, including
the nature and intensity of the respiratory symp-
toms, asthma triggering factors (including aller-
gens) and medication needs. Atopy was confirmed
by skin-prick tests with 16 common allergens
including cat, dog, horse, mixed trees, birch,
mixed grasses, ragweed, Dermatophagoides fari-
nae, Dermatophagoides pteronyssinus, Alternaria,
Hormodendrum and cockroach. Normal saline and
histamine were used as negative and positive
controls, respectively. A positive response was
defined as a skin wheal diameter of 3mm or more
at 15min. Allergens were provided by the coordi-
nating center for all centers.
Spirometry was done according to current Amer-
ican Thoracic Society (ATS) standards, using three
reproducible measurements of FEV1 before inhala-
tion of 200 mg salbutamol.19 Measurements were
obtained with a calibrated spirometer meeting ATS
recommendations.20
Methacholine challenges were done at the same
time of day, in the morning, according to the
method described by Juniper et al.21 PC20 was
obtained by interpolation of the dose–response
curve at 20% fall in FEV1. At the end of the
methacholine test, the patient was asked if he
had experienced similar symptoms in the past
as those induced by methacholine inhalation.Perception of bronchoconstriction-induced breath-
lessness was assessed using a modified Borg Scale
from 0 to 10.22
Sputum was induced by the method described by
Pin et al.23 and modified by Pizzichini.24 Briefly,
subjects were pre-treated with 200 mg of salbuta-
mol before inhaling increasing concentrations of
hypertonic saline (3%, 4% and 5%) for 7min each
(for a maximum of 21min) with a Medix electronic
nebulizer (Medix, Catthorp, England) without a
valve or nose clip. After each inhalation, subjects
were instructed to blow their nose, rinse their
mouth and swallow the water to minimize post-
nasal drip and squamous epithelial cell contamina-
tion, respectively, before trying to expectorate in a
sterile container. Mucus obtained that way was
then separated from saliva using forceps, weighed,
and rocked with four times its volume of dithio-
threitol (Sputolysin; Calbiochem Corp., La Jolla,
CA, USA) during 15min. The reaction was stopped
by adding an equal volume of Dulbecco’s phos-
phate-buffered saline (D-PBS) 1 (Invitrogen,
Burlington, Ont., Canada). The cellular suspension
was centrifuged at 800 g during 4min and the
supernatant was collected and frozen at 80 1C for
further analysis. The cells were then resuspended
in D-PBS 1 and slides were prepared with a
Cytospin 3 (Shandon Scientific Ltd., Astmoor,
England) and colored with Diff-Quik solutions (Dade
Diagnostics Inc., Aguada, PR, USA) for a count of
400 cells.
Sputum supernatant ECP levels were determined
by the automated UniCAP method (Pharmacia
Diagnostics, Mississauga, Ont., Canada) while levels
of a2-macroglobulin (a2-M) were determined by
ELISA. The detection limits for ECP and a2-M were
2 mg/l and 3 mg/ml, respectively.Statistical analysis
Results of representative measures were expressed
using mean7SD. Analyses of all parameters were
performed using one-way ANOVA. For some vari-
ables, the graphical analyses of residuals with
predicted values revealed a relationship between
the variances of the observations and the means for
these variables. The logarithm was the estimate
form of the required transformation associated
with these variables to stabilize the variance.25
Statistical results from these parameters were
expressed with transformed values. The normality
assumption was verified with the Shapiro–Wilk test
and the Brown and Forsythe’s variation of Levene’s
test statistic was used to verify the homogeneity of
variances. All assumptions were fulfilled. A similar
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Table 1 Subjects’ characteristics.
Parameter Asymptomatic
airway hyper-
responsiveness
Recently diagnosed
asthma (o5 years)
Longer-standing
asthma (X5 years)
Sex, n (%)
Male 7 (30) 11 (36.7) 16 (53.3)
Female 20 (70) 19 (63.3) 14 (46.7)
Age (years), mean (SD) 28 (7.9) 26 (6.5) 26 (6.9)
Duration of asthma (years), mean (SD) N/A 0.8 (1.5) 12.8 (8.1)
Smoking, n (%)
Non-smoker 21 (77.8) 24 (80) 22 (77.8)
Ex-smoker 6 (22.2) 6 (20) 8 (22.2)
FEV1
(l), Mean (SD) 3.41 (0.65) 3.59 (0.67) 3.38 (0.59)
(% predicted), mean (SD) 101 (15) 100 (12) 93 (10)y
FVC
(l), Mean (SD) 4.06 (0.82) 4.27 (0.86) 4.19 (0.87)
(% predicted), mean (SD) 102 (16) 101 (13) 97 (12)
Atopy
Animal, n (%) 16 (59) 26 (87) 23 (77)
Pollen, n (%) 16 (59) 26 (87) 23 (77)
House-dust mite, n (%) 23 (85) 24 (80) 25 (83)
Others, n (%) 18 (67) 28 (93) 28 (93)
PC20 (mg/ml), geometric mean (SD) 5.7 (2.3) 4.9 (2.3) 2.9 (2.2)
y
Borg score at 20% fall in FEV1 (0–10)
mean (SD)
1.5 (1.8) 2.1 (1.8) 2.1 (1.3)y
Maximum Borg score (0–10) mean (SD) 3.3 (1.3) 2.75 (2.4) 2.4 (1.5)
% Fall in FEV1 at max Borg score mean
(SD)
26.1 (8.2) 28.4 (8.2) 28.8 (12.1)
Asymptomatic AHR: Asymptomatic airway hyperresponsiveness.
Ex-smoker: Smoking o10 pack-years and no smoking in the last year.
ySignificantly different from asymptomatic AHR (Po0:05).
Mild asthma vs. asymptomatic AHR 295approach was performed to analyze data expressed
in percentage using the square root arcsinus
transformation. Relationships between parameters
were expressed with the Pearson’s correlation
coefficients. The results were considered signifi-
cant with P-values p0:05. The data were analyzed
using the statistical package program SAS v8.2 (SAS
Institute Inc., Cary, NC).Results
A total of 87 subjects took part to this study. They
included 60 subjects with mild asthma, either with
a recently diagnosed ðn ¼ 30Þ or with longer-
standing asthma ðn ¼ 30Þ and 27 subjects with
asymptomatic AHR, with a respective mean age of
26:0 6:5, 26:0 6:9 and 28 7:9 years. Mean7SD
duration of asthma was 0:8 1:5 years for subjects
with recently diagnosed asthma and 12:8 8:1years for those with longer-standing asthma. Sub-
jects’ characteristics are summarized in Table 1.
Expiratory flows
Mean FEV1 and mean predicted forced vital
capacity (FVC) were similar in the three groups
except for the percent predicted FEV1, which was
lower in longer-standing asthma than in asympto-
matic AHR (Po0:05, Table 1).
Methacholine responsiveness and perception
of bronchoconstriction
Mean7SD PC20 was 4:9 2:3 in recently diagnosed
asthma, 2:9 2:2 in longer-standing asthma and
5:7 2:3 in asymptomatic subjects. PC20 values
were significantly different between all groups
except for recently diagnosed asthma versus
asymptomatic subjects. Mean perception scores at
ARTICLE IN PRESS
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Figure 1 Perception score at 20% fall in FEV1 in the 3
groups of subjects. Median is represented by the bars. A
significant difference was found between asymptomatic
AHR and LSA. RDA: Recently diagnosed asthma; LSA:
Longer-standing asthma, Asymptomatic AHR: Asympto-
matic airway hyperresponsiveness; FEV1: Forced expira-
tory volume in 1 s.
L.-P. Boulet et al.29620% fall in FEV1 were lower in asymptomatic
subjects compared to longer-standing asthma (Ta-
ble 1, Fig. 1).Airway inflammation and correlation with
other parameters
Induced sputum analysis showed a higher number of
total cell counts in recently diagnosed asthma than
in the two other groups (Po0:05, Table 2).
However, median (25%, 75% interquartile) eosino-
phil percentages were similar in the three groups
(P40:05); 33% of recently diagnosed and 24% of
longer-standing asthmatic subjects had more than
2% eosinophils on induced sputum compared with
28% in asymptomatic AHR (data not shown). Mean
total eosinophil counts were not significantly
different between the three groups (Table 2).
Macrophages and neutrophils total absolute num-bers were higher in recently diagnosed asthma
although this was not different in percentage of
cells. Total number of lymphocytes was lower in
longer-standing asthma. Bronchial epithelial cells
were similar in the three groups.
There were no correlations between induced
sputum eosinophils, other types of white blood
cells or total cell counts, with either FEV1, FVC,
PC20, perception score at 20% fall in FEV1 or D
perception score/D FEV1 in either group.
There was a strong overall correlation between
ECP levels and both total counts and percentage of
eosinophils (r ¼ 0:83 and 0.63, respectively,
Po0:0001) for the totality of subjects. There were
no differences in ECP or a2-macroglobulin levels
between the three groups (P40:05, Table 2).Discussion
This study showed that subjects with asymptomatic
AHR have airway inflammatory features such as
induced sputum eosinophil counts, ECP and a2-
macroglobulin levels similar to mild asthmatic
subjects either with a recently diagnosed asthma
or a longer-standing asthma. However, asthmatic
patients with recently diagnosed asthma had an
increased total numbers of cells and a trend
towards an increased ECP, in sputum, although this
last was not significant. Mean PC20 was slightly
lower in longer-standing asthma than in asympto-
matic AHR, in keeping with one of our previous
studies.26 There were no significant correlations in
either group between airway inflammation and
breathlessness perception scores at 20% fall in
FEV1.
In recently diagnosed asthma, an important
increase in total, neutrophil and macrophage cell
counts was observed compared with asymptomatic
AHR and longer-standing asthma. It may suggest
that over time, airway inflammation decreases and
that the changes in airway function could mostly be
due to airway remodeling, as in subjects with
asymptomatic AHR. A previous study by our group26
did not suggest that there was such a difference in
baseline airway inflammation according to the
duration of asthma but in the present study, the
definition of long-standing asthma was different
and we had a larger number of subjects. This raises
the possibility that an increase in the airway
inflammatory process in a predisposed individual
leads to the development of asthma. This is
supported by our previous observations on asymp-
tomatic AHR showing that the development of
asthma in this group is associated with an increased
ARTICLE IN PRESS
Table 2 Induced sputum measurements
Parameter Asymptomatic
airway hyper-
responsiveness
Recently diagnosed
asthma (o5 years)
Longer-standing
asthma (X5 years)
Total number of cells (106 cells),
mean (SD)
0.301 (0.239) 1.407 (2.680) 0.366 (0.431)
Total cell counts (106 cells) mean (SD)
Macrophages 0.215 (0.195) 0.588 (0.644) 0.209 (0.214)
Neutrophils 0.054 (0.078) 0.893 (2.411) 0.123 (0.185)
Lymphocytes 0.020 (0.039) 0.023 (0.063) 0.003 (0.003)y
Eosinophils 0.004 (0.005) 0.019 (0.019) 0.010 (0.036)
Bronchial epithelial cells 0.007 (0.012) 0.007 (0.012) 0.020 (0.073)
Differential cell counts (%), median (25–75% interquartiles)
Macrophages 77.0 (57.4–84.3) 67.9 (48.7–78.6) 71.1 (59.8–82.8)
Neutrophils 10.8 (5.5–36.3) 25.1 (16.0–44.1) 22.3 (13.3–32.1)
Lymphocytes 1.6 (0.8–6.0) 1.5 (1.0–2.5) 0.9 1.3 (0.5–1.8)
Eosinophils 0.9 (0.12.2) 0.9 (0.52.2) (0.41.9)
Bronchial epithelial cells 1.1 (0.83.4) 1.4 (0.72.0) 1.2 (0.92.3)
ECP levels (ng/ml) median (25–75%
interquartiles)
14.1 (8.231.6) 34.3 (13.555.4) 23.1 (6.679.1)
a2-macroglobulin levels (mg/ml) mean
(SD)
19.9 (18.9) 13.8 (8.9) 27.2 (27.4)
n ¼ 25
*Significantly different from longer-standing asthma and asymptomatic AHR (Po0:05).
ySignificantly different from recently diagnosed asthma and asymptomatic AHR (Po0:05).
Mild asthma vs. asymptomatic AHR 297airway inflammation and a reversal of the CD4+
over CD8+ ratio, although it is also associated with
an increased in airway remodeling.
This study also shows that perception of bronch-
oconstriction was slightly lower in asymptomatic
AHR than in longer-standing asthma, although it is
unlikely that this explains why these subjects do
not experience any symptoms. In this regard, it was
previously suggested that subjects with asympto-
matic AHR were less likely to report an increase in
dyspnea score during histamine bronchoprovoca-
tion compared to subjects with symptomatic AHR.27
Other reports on children and adults with asympto-
matic AHR, however, including some studies from
our laboratory, showed that these subjects were
generally able to perceive bronchoconstriction
adequately.6,28,29 We nevertheless cannot exclude
that a lower perception of induced symptoms could
be a contributing factor to their asymptomatic
status.
Most of our subjects had mild AHR, although PC20
was slightly lower in asthmatic subjects with a
longer-standing asthma. We previously observed
that asymptomatic subjects with AHR had increases
in airway responsiveness when they developed
symptoms of asthma over a period of 2 years.30 In
another study on mild asthmatic patients, inkeeping with the present study, those with a long
duration of asthma had a significantly higher
degree of AHR compared to recently diagnosed
asthma.26
Nevertheless, there was no significant correla-
tion between perception of bronchoconstriction-
induced breathlessness and PC20. This may suggest
that there is a threshold of airway responsiveness in
a given individual at which symptoms begin to be
perceived. This may be related to associated
increased variations in expiratory flows following
environmental triggers or the development of other
physiological abnormalities such as lung hyperinfla-
tion, which has been thought to contribute to
respiratory symptomatology.31,32 Previous studies
had also shown a slight increase in diurnal variation
of peak expiratory flows in asymptomatic subjects
with AHR compared to normal subjects but lower
than in asthmatic subjects.29,30
Other possible causes of this absence of symp-
toms in the presence of AHR could have been the
absence of airway inflammation in the asympto-
matic AHR group. However, we found that there
was a similar degree of airway inflammation in
all groups, at least for eosinophils and markers
of eosinophil activation or plasma transudation
such as ECP and a2-macroglobulin.
33 Nevertheless,
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matory cells at the level of medium to large
airways and it may not always reflect airway wall
inflammation.34 As bronchial biopsies and induced
sputum sampling assess different airway compart-
ments and aspects of the inflammatory process, it
is not surprising that there are only weak correla-
tions between these measures.35,36 In this regard,
our results differ from some of our previous findings
on bronchial biopsies, in which the number and
state of activation of inflammatory cells were
higher in asymptomatic AHR than in normal controls
but lower than in mild asthma.30 However, the way
in which airway eosinophilia may contribute to the
development of symptoms is unclear. Airway edema
is another inflammatory change that could influ-
ence airway function and increase changes in
airway caliber. However, we found no significant
difference in a marker of plasma transudation, a2-
macroglobulin. There may be other components of
the inflammatory process that differ in the two
groups, however. It is possible that differences in
airway remodeling between asthma and asympto-
matic AHR, as we previously reported, are involved
in the expression of symptoms, and this should be
further explored.
Finally, it may be possible that some subjects do
not report symptoms because they are not exposed
enough to triggers or they do not interpret those
symptoms as due to asthma. This did not seem the
case in our subjects as they had no previous
symptoms such as those experienced during
bronchoprovocation. In the context of this study,
we did not include a group of atopic subjects
without AHR, our focus being only in subjects with
AHR, either symptomatic or not, as the question
was to help determine why some subjects with AHR
had no symptoms.
In conclusion, we found no significant differences
in markers of airway inflammation in mild asthma
compared with asymptomatic AHR. Although per-
ception of bronchoconstriction was slightly lower in
asymptomatic subjects, the significance of such
mild reduction in perception is uncertain and
further studies should explore why these patients
have no symptoms.Acknowledgments
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